Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

Inclusion Criteria

• •1. Are willing and able to give informed consent;
• •2. Are at least 18 years of age;
• •3. Are willing to comply with all study requirements, evaluations, and procedures
• •4. Have 1 clinically typical, visible nodular BCC lesion which meets the following criteria:
• •* a primary lesion (not recurrent, not previously treated or biopsied)
• •* non-infected
• •* size between 0.25 and 1.5 cm2
• •* located at least 1 cm from the eyes, nose, mouth, ear, and hairline to exclude the H-zone of the face
• •* clinically consistent with nodular BCC
• •* histologically consistent with nodular BCC and have no histological evidence of a morpheaform or micronodular pattern
• •* suitable for treatment with surgical excision
• •* easily identifiable and treatable by subject or reliable subject representative
• •5. Are free of any significant physical abnormalities or previous scarring in the potential application site area that may cause difficulty with examinations.
• •6. Are willing to stop using over-the-counter retinol products or products containing alpha or beta hydroxyacids in the treatment and surrounding area 8 hours prior to treatment with the imiquimod cream and clinic visits.